Primary Podocytopathies After COVID-19 Vaccination

Timmermans, Sjoerd A.M.E.G.; Busch, Matthias; Abdul‐Hamid, Myrurgia A.; Frenken, L.A.M.; Aarnoudse, Albert-Jan L.H.J.; Paassen, Pieter van

doi:10.1016/j.ekir.2021.12.023

Cited by 13 publications

(14 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased numbers of newly diagnosed MCD were recently reported for 2021 in a Dutch observational cohort. 23 However, that cohort-based study could not calculate true population-based incidence, and only 5 of 11 cases had received any SARS-CoV-2 vaccine before presentation, which makes a true association with vaccination questionable. In our study, the incidence of MCD during the vaccination campaign did not cross the upper boundary of the 95% credible interval for the predicted incidence, and the risk J o u r n a l P r e -p r o o f ratio for the development of MCD in vaccinated vs. unvaccinated persons was not significantly different from one.…”

Section: Discussionmentioning

confidence: 98%

Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased

Diebold

Locher

Boide

et al. 2022

Kidney International

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased

Diebold

Locher

Boide

et al. 2022

Kidney International

View full text Add to dashboard Cite

“…Typical clinical and pathologic MCD features were confirmed in our case, which may be due to the potent immune response of the COVID-19 vaccine. Timmermans et al also reported that biopsy-proven primary podocytopathies were significantly increased after COVID-19 vaccination compared with those before the COVID-19 pandemic, and incidences of MCD have since mainly increased [10]. These findings suggest a potential link between COVID-19 vaccinations and MCD.…”

Section: Discussionmentioning

confidence: 93%

“…It has also been confirmed that podocyte injury is caused by various circulating cytokines, such as interleukin (IL)-4, 5, 9, 10, and 13, which are released by activated T lymphocytes [3,9]. Recently, a Netherlands registry study showed podocyte-associated punctate polyclonal IgG deposits in MCD after COVID-19 vaccination, so B cell activation may also contribute to the onset of MCD to some degree [10]. Typical clinical and pathologic MCD features were confirmed in our case, which may be due to the potent immune response of the COVID-19 vaccine.…”

Section: Discussionmentioning

confidence: 98%

“…The patients responded well to steroid treatment, as did the general MCD cases. Some new-onset or relapse MCD cases after COVID-19 vaccination were reported, and most of them responded well to the high-dose steroid treatment and showed rapid remission [4,[10][11][12][13]. However, one case showed no response to the high-dose steroid treatment, and complete remission was achieved after the administration of rituximab [4].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

New-Onset Kidney Diseases after COVID-19 Vaccination: A Case Series

et al. 2022

View full text Add to dashboard Cite

Various vaccines against COVID-19 have been developed and proven to be effective, but their side effects, especially on kidney function, are not yet known in detail. In this study, we report the clinical courses and histopathologic findings of new-onset kidney diseases after COVID-19 vaccination as confirmed via kidney biopsy. Five patients aged 42 to 77 years were included in this study, and baseline kidney function was normal in all patients. The biopsy-proven diagnosis indicated newly developed kidney diseases: (1) IgA nephropathy presenting with painless gross hematuria, (2) minimal change disease presenting with nephrotic syndrome, (3) thrombotic microangiopathy, and (4) two cases of acute tubulointerstitial nephritis presenting with acute kidney injury. Individualized treatment was applied as per disease severity and underlying pathology, and the treatment outcomes of all patients were improved. Since this is not a controlled study, the specific pathophysiologic link and causality between the incidence of kidney diseases and COVID-19 vaccination are difficult to confirm. However, clinicians need to consider the possibility that kidney diseases may be provoked by vaccines in patients who have renal symptoms.

show abstract

“…Increased numbers of newly diagnosed MCD were recently reported for 2021 in a Dutch observational cohort. 20 However, that cohort-based study could not calculate true population-based incidence, and only 5 of 11 cases had received any SARS-CoV-2 vaccine before presentation, which makes a true association with vaccination questionable. In our study, the incidence of MCD during the vaccination campaign did not cross the upper boundary of the 95% credible interval for the predicted incidence, and the risk ratio for the development of MCD in vaccinated vs. unvaccinated persons was not significantly different from one.…”

Section: Discussionmentioning

confidence: 98%

Incidence of Glomerulonephritis after SARS-CoV-2 mRNA Vaccination

Diebold

Locher

Boide

et al. 2022

Preprint

View full text Add to dashboard Cite

Numerous cases of glomerulonephritis manifesting shortly after SARS-CoV-2 vaccination have been reported, but causality remains unproven. We studied the association between mRNA-based SARS-CoV-2 vaccination and new-onset glomerulonephritis using a nationwide retrospective cohort and case-cohort design. Data from all Swiss pathology institutes processing native kidney biopsies served to calculate incidence of IgA nephropathy, pauci-immune necrotizing glomerulonephritis, minimal change disease and membranous nephropathy. The observed incidence during the vaccination campaign (Jan to Aug 2021) was not different from the expected incidence based on the years 2015 to 2019 (incidence rate ratio 0.86, 95%-credible interval 0.73–1.02) and did not cross the upper boundary of the 95% credible interval for any month. Among 111 patients aged >18 years with newly diagnosed glomerulonephritis between January and August 2021, 38.7% had received at least one vaccine dose before biopsy, compared to 39.5% of the general Swiss population matched for age and calendar-time. The estimated risk ratio for the development of new-onset biopsy-proven glomerulonephritis was 0.97 (95% CI 0.66–1.42, P=0.95) in vaccinated vs. unvaccinated individuals. Patients with glomerulonephritis manifesting within 4 weeks after vaccine did not differ clinically from the rest of the cohort. Results were consistent across all types of glomerulonephritis with the possible exception of minimal change disease. In conclusion, vaccination against SARS-CoV-2 was not associated with new-onset glomerulonephritis in these two complementary studies. Most temporal associations between SARS-CoV-2 vaccination and glomerulonephritis are likely coincidental.

show abstract

Primary Podocytopathies After COVID-19 Vaccination

Cited by 13 publications

References 8 publications

Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased

Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased

New-Onset Kidney Diseases after COVID-19 Vaccination: A Case Series

Incidence of Glomerulonephritis after SARS-CoV-2 mRNA Vaccination

Contact Info

Product

Resources

About